The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
miR-34 – a microRNA replacement therapy is headed to the clinic
Open accessAbstract
MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L., & Weinberg, R. A. (2009) · Cell · doi:10.1016/j.cell.2009.03.047 · Cited by 820
RetractedTwo new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
RAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 1×
“And yet, the collective repression of a wide range of target genes is likely to a have a significant impact on cellular phenotypes (Selbach et al., 2008).”
BackgroundA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
Self-citationTranscriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
A microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
Suppression of non-small cell lung tumor development by the let-7 microRNA family
Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., & Jacks, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712321105 · Cited by 843
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., DeSano, J. T., Bommer, G. T., Fan, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006816 · Cited by 689
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Self-citationTrang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Self-citationThe Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Self-citationThe let-7 microRNA reduces tumor growth in mouse models of lung cancer
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., & Slack, F. J. (2008) · Cell Cycle · doi:10.4161/cc.7.6.5834 · Cited by 593
Self-citationNanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., Sun, Z., & Zheng, X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.03.057 · Cited by 514
Yin Yang 1 Is a Negative Regulator of p53
Sui, G., Affar, E. B., Shi, Y., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P., Calvo, D., Grossman, S. R., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.004 · Cited by 424
Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., & Zheng, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.09.035 · Cited by 418
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
Ji, Q., Hao, X., Meng, Y., Zhang, M., DeSano, J., Fan, D., & Xu, L. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-266 · Cited by 394
miR-34 miRNAs provide a barrier for somatic cell reprogramming
Choi, Y. J., Lin, C.-P., Ho, J. J., He, X., Okada, N., Bu, P., Zhong, Y., Kim, S. Y., Bennett, M. J., Chen, C., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2366 · Cited by 382
Liu, X., Sempere, L. F., Ouyang, H., Memoli, V. A., Andrew, A. S., Luo, Y., Demidenko, E., Korc, M., Shi, W., Preis, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39566 · Cited by 373
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.109 · Cited by 352
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells
Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.086 · Cited by 331
A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene
Cole, K. A., Attiyeh, E. F., Mosse, Y. P., Laquaglia, M. J., Diskin, S. J., Brodeur, G. M., & Maris, J. M. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2102 · Cited by 316
Vogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., Steinstraesser, L., Tannapfel, A., & Hermeking, H. (2011) · Virchows Archiv · doi:10.1007/s00428-010-1030-5 · Cited by 309
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, H. S., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
The MYCN oncogene is a direct target of miR-34a
Wei, J. S., Song, Y. K., Durinck, S., Chen, Q.-R., Cheuk, A. T. C., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A., Shohet, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.154 · Cited by 296
Hashimi, S. T., Fulcher, J. A., Chang, M. H., Gov, L., Wang, S., & Lee, B. (2009) · Blood · doi:10.1182/blood-2008-09-179150 · Cited by 291
miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes
Hsu, S.-D., Chu, C.-H., Tsou, A.-P., Chen, S.-J., Chen, H.-C., Hsu, P. W.-C., Wong, Y.-H., Chen, Y.-H., Chen, G.-H., & Huang, H.-D. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1012 · Cited by 290
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011) · Oncogene · doi:10.1038/onc.2011.13 · Cited by 252
Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies
Wong, K. Y., So, C. C., Loong, F., Chung, L. P., Lam, W. W. L., Liang, R., Li, G. K. H., Jin, D.-Y., & Chim, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019027 · Cited by 247
Wang, X., Wang, H.-K., McCoy, J. P., Banerjee, N. S., Rader, J. S., Broker, T. R., Meyers, C., Chow, L. T., & Zheng, Z.-M. (2009) · RNA · doi:10.1261/rna.1442309 · Cited by 237
Yan, D., Zhou, X., Chen, X., Hu, D.-N., Dong, X. D., Wang, J., Lu, F., Tu, L., & Qu, J. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2681 · Cited by 211
E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis
Lizé, M., Pilarski, S., & Dobbelstein, M. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.188 · Cited by 209
Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205
Kaller, M., Liffers, S.-T., Oeljeklaus, S., Kuhlmann, K., Röh, S., Hoffmann, R., Warscheid, B., & Hermeking, H. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010462 · Cited by 201
Kuo, K.-T., Guan, B., Feng, Y., Mao, T.-L., Chen, X., Jinawath, N., Wang, Y., Kurman, R. J., Shih, I.-M., & Wang, T.-L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3913 · Cited by 196
Yan, K., Gao, J., Yang, T., Ma, Q., Qiu, X., Fan, Q., & Ma, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033778 · Cited by 195
Akao, Y., Noguchi, S., Iio, A., Kojima, K., Takagi, T., & Naoe, T. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.006 · Cited by 181
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
Mraz, M., Malinova, K., Kotaskova, J., Pavlova, S., Tichy, B., Malcikova, J., Stano Kozubik, K., Smardova, J., Brychtova, Y., Doubek, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.377 · Cited by 177
de Antonellis, P., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., De Vita, G., Carotenuto, M., Bello, A., Formiggini, F., Galeone, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024584 · Cited by 171
Du, R., Sun, W., Xia, L., Zhao, A., Yu, Y., Zhao, L., Wang, H., Huang, C., & Sun, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030771 · Cited by 169
Craig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., Schlapbach, R., Dirnhofer, S., Tzankov, A., & Müller, A. (2011) · Blood · doi:10.1182/blood-2010-10-312231 · Cited by 166
Tryndyak, V., Ross, S. A., Beland, F. A., & Pogribny, I. P. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20484 · Cited by 162
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Arceci, R. J. (2009) · Yearbook of Oncology · doi:10.1016/s1040-1741(09)79352-2 · Cited by 159
Epigenetic inactivation of the miR-34a in hematological malignancies
Chim, C. S., Wong, K. Y., Qi, Y., Loong, F., Lam, W. L., Wong, L., Jin, D., Costello, J., & Liang, R. H. S. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq033 · Cited by 157
miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53
Navarro, F., Gutman, D. A., Meire, E., Cáceres, M., Rigoutsos, I., Bentwich, Z., & Lieberman, J. (2009) · Blood · doi:10.1182/blood-2009-02-205062 · Cited by 155
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
McCullough, A. E. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.022 · Cited by 142
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma
Weeraratne, S. D., Amani, V. M., Neiss, A., Teider, N., Scott, D. K., Pomeroy, S. L., & Cho, Y. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq179 · Cited by 135
Silber, J., Skanderup, A. J., Ozawa, T., Harinath, G., Pedraza, A. M., Sander, C., Holland, E. C., & Huse, J. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033844 · Cited by 130
Maes, O. C., Sarojini, H., & Wang, E. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21834 · Cited by 127
CpG island methylation status of miRNAs in esophageal squamous cell carcinoma
Chen, X., Hu, H., Guan, X., Xiong, G., Wang, Y., Wang, K., Li, J., Xu, X., Yang, K., & Bai, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26171 · Cited by 116
MicroRNA-34a: A Novel Tumor Suppressor in p53-mutant Glioma Cell Line U251
Luan, S., Sun, L., & Huang, F. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.02.007 · Cited by 113
Li, W., Chen, C., Xu, M., Guo, J., Li, Y., Xia, Q., Liu, H., He, J., Yu, H., & Zhu, L. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08075.x · Cited by 111
Vinall, R., Ripoll, A., Wang, S., Pan, C., & White, R. D. D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26256 · Cited by 110
Craig, V. J., Tzankov, A., Flori, M., Schmid, C. A., Bader, A. G., & Mueller, A. (2012) · Leukemia · doi:10.1038/leu.2012.110 · Cited by 107
Self-citationLi, B., Hu, Y., Ye, F., Li, Y., Lv, W., & Xie, X. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181d63170 · Cited by 105
Asslaber, D., Hofbauer, J. P., Seyfried, I., Desch, P., Stöcher, M., Tinhofer, I., Egle, A., Merkel, O., & Greil, R. (2010) · Blood · doi:10.1182/blood-2009-07-234823 · Cited by 103
Shen, Z.-S., Zhan, G., Ye, D., Ren, Y., Cheng, L.-X., Wu, Z.-H., & Guo, J. (2012) · Medical Oncology · doi:10.1007/s12032-011-0156-x · Cited by 99
Ichimura, A., Ruike, Y., Terasawa, K., Shimizu, K., & Tsujimoto, G. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063321 · Cited by 94
Systematic Proteome Analysis Identifies Transcription Factor YY1 as a Direct Target of miR-34a
Chen, Q., Yu, L., Tsang, P., Wei, J. S., Song, Y., Cheuk, A., Chung, J., Hewitt, S. M., Veenstra, T. D., & Khan, J. I. (2010) · Journal of Proteome Research · doi:10.1021/pr1006697 · Cited by 89
Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs
Greenberg, E., Hershkovitz, L., Itzhaki, O., Hajdu, S. D., Nemlich, Y., Ortenberg, R., Gefen, N., Edry, L., Modai, S., Keisari, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018936 · Cited by 86
MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme
Li, W., Ma, M., Dong, L., Wang, F., Chen, L., & Li, X. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.16300 · Cited by 77
A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH
Kim, H.-R., Roe, J., Lee, J., Hwang, I., Cho, E., & Youn, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.077 · Cited by 41
Erlotinib: Success of A Molecularly Targeted Agent For the Treatment of Advanced Pancreatic Cancer
Welch, S. A., & Moore, M. J. (2007) · Future Oncology · doi:10.2217/14796694.3.3.247 · Cited by 24
Creating a flexible multiple microRNA expression vector by linking precursor microRNAs
Qiu, X., Friedman, J. M., & Liang, G. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.123 · Cited by 11
Cheung, L., Jayne, E., Haber, M., & Murray, D. (2013) · InTech eBooks · doi:10.5772/54813 · Cited by 4
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Metadata
- Authors
- Bader, A. G.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 120-120
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2140477106
- Cited by
- 728
- References
- 84
- FWCI
- 20.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.